Hormone Receptor Status and its Relation to C-Reactive Protein and other Prognostic factors in Breast Cancer in Jableh-Syria

Breast cancer is the most common form of cancer among women worldwide, with the increase incidence and its associated morbidity, mortality, and enormous treatment costs, there is a great interest in strategies of prevention and detection of early prognostic factors. Serum CRP levels could be a marker of increased risk for breast cancer.

Evaluation of estrogen-receptor ER, progesterone-receptor PR and human epidermal growth factor receptor 2 Her-2 expression in 60 female-patients of breast cancer in Jableh-Syria, and studying their relation with serum CRP levels and other prognostic factors.

60 female-patients of breast cancer aged between 32 to 77 years old, admitted in National hospital of Jableh (Jableh-Syria) were selected from December 2015 until December 2016. Blood samples were collected for CRP levels on admission and measured by immunoturbidimetric determination, levels >5mg/l were considered positive. ER-receptor, PR-receptor and Her-2 expression were assessed.

Triple positive receptors TP was the major subgroup of patients (n=21, 35%, p. value= 0.049). Relation between ER-receptor and PR-receptor expression was strongly significant (n= 37, 90.24%, p. value < 0.0001), Patients positive for Her-2 receptor expression were ≥46 years (n=27, 84.38%, p, value=0.039). Patients positive for serum CRP levels were positive for ER-receptor expression (n=26, 63.41%, p. value=0.021). Mean of CRP levels were increased with stage and difference was not significant. Patients with positive lymph nodes count >4 had higher grade (n=28, 75.78%, p. value= 0.009) and stage (n=24, 64.86%, p. value= 0.002), and were positive for PR-receptor expression (n=31, 83.71%, p. value= 0.008).

90% of patients have same histological diagnosis (invasive ductal carcinoma IDC), but present high variety of ER-receptor, PR-receptor and Her-2 receptor expression as heterogenic subtypes breast cancer, which propose different strategies of prevention and protocols of therapy. CRP levels could be a biomarker for invasive and progression of cancer according to stage and pN staging. Serum CRP levels could predict patients positive for ER-receptor, those who will benefit of modulation of ER-receptor expression as a routine strategy of prevention.